As of May 26
| +0.09 / +0.72%|
The 9 analysts offering 12-month price forecasts for Astellas Pharma Inc have a median target of 14.39, with a high estimate of 17.19 and a low estimate of 12.31. The median estimate represents a +14.21% increase from the last price of 12.60.
The current consensus among 10 polled investment analysts is to Hold stock in Astellas Pharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.